| Literature DB >> 35638044 |
Ridha Dharmajaya1, Dina Keumala Sari2.
Abstract
Introduction: Oxidative stress has been considered as one of many contributor in developing risk of cancer. Oxidative stress may also promote the increasing number of free radical. Malondialdehyde (MDA) is one of radical oxidative marker, while Superoxide Dismutase (SOD) play role as endogenous antioxidant. It has been postulated that in cancer cells there is an increase of oxidative stress compared to normal cell. Method: This study is a case controlled analytical study to find the relationship between levels of MDA and SOD in patients with brain tumours. The sample obtained was 35 people who met the inclusion and exclusion criteria. Based on this analysis, it will be determined whether there is a significant relationship between levels of MDA and SOD in each type of brain tumours. Result: There is no significant relationship from all groups brain tumour and all tumours have a low correlation (r = 0.187) in the value of superoxide dismutase level. There is also no significant relationship from all groups (p = 0.302) and a low correlation (r = 0.187) to the value of Malondialdehyde level. Discussion: There was no relationship between superoxide dismutase in any type of intracranial tumour in this study. These concluded that superoxide values could not be a risk factor for primary intracranial tumours. Levels of MDA which is an indicator of lipid peroxidation, were significantly higher in patients consisting of meningiomas and gliomas. In high grade gliomas, the MDA increases due to the progressive progression of glioma tumours due to an increase in Reactive oxygen species levels.Entities:
Keywords: Brain tumour; Endogenous antioxidant; Malondialdehyde; Neurooncology; Superoxide dismutase
Year: 2022 PMID: 35638044 PMCID: PMC9142402 DOI: 10.1016/j.amsu.2021.103231
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Sample gender and age.
| Description | Parameter | n |
|---|---|---|
| Gender | Men | 20 |
| Women | 15 | |
| Total | 35 | |
| Age | <20 | 3 |
| 21–30 | 3 | |
| 31–40 | 5 | |
| 41–50 | 15 | |
| 51–60 | 5 | |
| 61–70 | 4 | |
| Total | 35 |
Type of brain tumour.
| Description | Type | n |
|---|---|---|
| Type of Brain Tumour | Meningioma | 15 |
| Glioma | 10 | |
| Brain Metastasis | 10 | |
| Total | 35 |
Fig. 1SOD value in brain tumour.
Brain tumour and SOD.
| Brain Tumour | Superoxide Dismutase | p | r |
|---|---|---|---|
| Glioma | Normal | 0.66 | 0.187 |
| Meningioma | Low | ||
| Brain Metastases |
GCS and KPS.
| No | Description | Parameter | n |
|---|---|---|---|
| 1 | Glassgow coma Scale (GCS) | 3–8 | 0 |
| 9–12 | 2 | ||
| 13–15 | 33 | ||
| Total | 35 | ||
| 2 | Karnofsky Perfomance Score (KPS) | 100 | 33 |
| 90 | 2 | ||
| 80 | 0 | ||
| 70 | 0 | ||
| 60 | 0 | ||
| 50 | 0 | ||
| 40 | 0 | ||
| 30 | 0 | ||
| 20 | 0 | ||
| 10 | 0 | ||
| 0 | 0 | ||
| Total | 35 |
Tukey HSD test in SOD level between tumour group.
| Brain Tumour | SOD level | |
|---|---|---|
| Δ | P value | |
| Meningioma vs glioma | −0.853 | 0.998 |
| Meningioma vs brain metastasis | −1.102 | |
| Glioma vs brain metastasis | −1.1017 | |
Fig. 2MDA value in brain tumour.
Brain tumour and MDA.
| Brain Tumour | MDA | p | r |
|---|---|---|---|
| Glioma | Normal | 0.173 | 0.179 |
| Meningioma | High | ||
| Brain Metastases |
Tukey HSD test in MDA level between tumour group.
| Brain tumour | MDA Level | |
|---|---|---|
| Δ | P value | |
| Meningioma vs Glioma | −3,876 | 0.155 |
| Meningioma vs brain metastasis | −2,992 | 0.319 |
| Glioma vs brain metastasis | 0.878 | 0.918 |